US Stock MarketDetailed Quotes
OKYO OKYO Pharma
- 1.040
- 0.0000.00%
Close Aug 23 16:00 ET
- 0.943
- -0.097-9.33%
Post 20:02 ET
35.19MMarket Cap-1824P/E (TTM)
1.050High0.850Low7.38MVolume1.040Open1.040Pre Close8.76MTurnover30.14%Turnover RatioLossP/E (Static)33.84MShares3.07052wk High-5.98P/B25.47MFloat Cap0.80852wk Low--Dividend TTM24.49MShs Float7.000Historical High--Div YieldTTM19.23%Amplitude0.808Historical Low1.186Avg Price1Lot Size
OKYO Pharma Key Stats
Quarterly+Annual
YOY
| (FY)Mar 31, 2024 | (FY)Mar 31, 2023 | (FY)Mar 31, 2022 | (FY)Mar 31, 2021 | (FY)Mar 31, 2020 | (FY)Mar 31, 2019 | (FY)Mar 31, 2018 | (FY)Mar 31, 2017 | (FY)Mar 31, 2016 | (FY)Mar 31, 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -23.33%-9.49M | -40.73%-7.7M | -241.71%-5.47M | -33.12%-1.6M | 39.59%-1.2M | -74.87%-1.99M | -118.01%-1.14M | -15.25%-521.98K | 91.60%-452.92K | -159.83%-5.39M |
| Net income from continuing operations | -26.49%-16.8M | -113.65%-13.28M | -84.03%-6.22M | -108.50%-3.38M | 66.95%-1.62M | 75.69%-4.9M | -10,301.76%-20.17M | 66.03%-193.9K | 89.76%-570.72K | 33.37%-5.57M |
| Operating gains losses | 7.80%55.18K | 644.07%51.19K | -390.58%-9.41K | -76.73%3.24K | 1,292.03%13.92K | -100.01%-1.17K | --18.83M | ---- | -128.14%-18.72K | 99.76%66.51K |
| Depreciation and amortization | 1.82%3.87K | 62.89%3.8K | -82.22%2.33K | 119.28%13.11K | 2,644.97%5.98K | --217.8166 | --0 | ---- | ---- | ---- |
| Other non cash items | 2,912.53%3.46M | 86.31%114.99K | -25.64%61.72K | 93.73%83.01K | -98.40%42.85K | 1,429.06%2.69M | --175.67K | ---- | 26.36%-8.6K | -569.37%-11.68K |
| Change In working capital | -32.35%2.67M | 485.38%3.95M | -197.99%-1.02M | 460.14%1.04M | 5.50%186.53K | 593.80%176.81K | 107.43%25.48K | -550.57%-342.8K | 250.80%76.08K | -51.03%-50.45K |
| -Change in receivables | --0 | --0 | -86.65%27.38K | 267.09%205.07K | 6.41%-122.73K | -192.47%-131.14K | 148.99%141.82K | -657.65%-289.5K | 1,580.30%51.91K | 94.32%-3.51K |
| -Change in payables and accrued expense | -41.00%2.23M | 1,616.75%3.78M | -129.66%-249.09K | 171.54%839.78K | 0.43%309.27K | 364.71%307.95K | -118.25%-116.34K | -320.55%-53.3K | 151.48%24.17K | -265.83%-46.95K |
| -Change in other current assets | 162.50%440.26K | 120.91%167.72K | ---802.15K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | 0 | 4.43M | ||||||||
| Operating cash flow | -23.33%-9.49M | -40.73%-7.7M | -241.71%-5.47M | -33.12%-1.6M | 39.59%-1.2M | -74.87%-1.99M | -118.01%-1.14M | -15.25%-521.98K | 52.69%-452.92K | 53.85%-957.25K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | -254.46%-5.92K | 90.79%-1.67K | 86.35%-18.11K | -9,931.22%-132.67K | -1.32K | 0 | 87.48%-233.24K | 70.72%-1.86M | |
| Capital expenditure reported | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 84.83%-282.23K | 70.19%-1.86M |
| Net PPE purchase and sale | --0 | -254.46%-5.92K | 75.96%-1.67K | ---6.94K | --0 | ---1.32K | --0 | ---- | 1,596.85%48.99K | 97.38%-3.27K |
| Net other investing changes | ---- | ---- | ---- | 91.58%-11.17K | ---132.67K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | -254.46%-5.92K | 90.79%-1.67K | 86.35%-18.11K | -9,931.22%-132.67K | ---1.32K | --0 | ---- | 87.48%-233.24K | 70.72%-1.86M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -33.41%6.21M | 332.99%9.32M | -72.49%2.15M | 712.50%7.83M | 963.31K | 0 | -96.56%8.6K | -96.01%250.21K | ||
| Net issuance payments of debt | --0 | --2M | --0 | 27,839.94%7.58M | ---27.33K | --0 | ---- | ---- | -26.36%8.6K | --11.68K |
| Net common stock issuance | -15.22%6.21M | --7.32M | --0 | -76.78%230.02K | --990.64K | --0 | ---- | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | --0 | --0 | 13,468.18%2.15M | --15.87K | --0 | ---- | ---- | ---- | ---- | 75.92%238.53K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -33.41%6.21M | 332.99%9.32M | -72.49%2.15M | 712.50%7.83M | --963.31K | --0 | ---- | ---- | -96.56%8.6K | -96.01%250.21K |
| Net cash flow | ||||||||||
| Beginning cash position | 49.79%4.05M | -60.80%2.7M | 2,825.59%6.89M | -62.48%235.49K | -76.03%627.62K | -16.75%2.62M | -10.77%3.15M | -19.25%3.53M | -38.54%4.37M | -24.73%7.1M |
| Current changes in cash | -302.32%-3.28M | 148.91%1.62M | -153.42%-3.32M | 1,771.58%6.21M | 81.35%-371.42K | -74.98%-1.99M | -118.01%-1.14M | 22.96%-521.98K | 73.64%-677.55K | -18.39%-2.57M |
| Effect of exchange rate changes | 122.88%63.5K | 68.18%-277.54K | -295.89%-872.14K | 2,249.98%445.22K | ---20.71K | ---- | ---- | --0 | 28.53%-119.57K | -3.18%-167.31K |
| End cash Position | -79.56%826.85K | 49.79%4.05M | -60.80%2.7M | 2,825.59%6.89M | -62.48%235.49K | -68.74%627.56K | -33.15%2.01M | -15.84%3M | -18.26%3.57M | -38.54%4.37M |
| Free cash flow | -23.24%-9.49M | -40.80%-7.7M | -240.34%-5.47M | -33.70%-1.61M | 39.63%-1.2M | -74.98%-1.99M | -118.01%-1.14M | 29.03%-521.98K | 73.93%-735.47K | 66.70%-2.82M |
| Currency Unit | USD | USD | USD | USD | USD | USD | GBP | GBP | GBP | GBP |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg